RNA interference target for treating aids

a technology of interference target and target gene, applied in the field of molecular biology, cell biology and gene therapy, can solve the problems of inability to completely eradicate the virus in vivo, and the target gene expression of rna interference targets that meet the requirements of conventional design can be inhibited effectively

Inactive Publication Date: 2011-10-06
XIAMEN UNIV +1
View PDF3 Cites 58 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

In one embodiment, the recombinant expression vector of the present invention is characterized in that it comprises a nucleic acid sequence encoding the siRNA and / or the miRNA and / or the ribozymes and / or the anti-sense oligonucleotide of the RNA interference target sequence provided by the present invention, wherein the nucleic acid sequence is operably linked with the expression controlling sequence, making it possible to express the siRNA and / or the miRNA and / or the ribozymes and / or the anti-sense oligonucleotide targeting HIV in animal cells (especially mammalian cells, such as human cells, HIV receptor cells, preferably CD4+cells, such as mammalian stem cells, preferably hematopoietic stem cells).
The present invention also involves a cell carrying in or outside of its genome the nucleic acid sequence encoding the RNA interference target according to the present invention, including a prokaryotic cell (for example a bacterial cell, such as a E. coli cell) and a eukaryotic cell (such as a fungal cell, an insect cell, a plant cell, an animal cell, preferably a mammalian cell, such as a human cell, preferably a HIV receptor cell and a stem cell, such as a CD4+cell and a CD34+cell), which contains the nucleic acid sequence encoding the RNA interference target according to the present invention, wherein these nucleic acid sequences can be operably linked with the expression controlling sequence, making it possible to express the siRNA and / or the miRNA and / or the ribozyme, and / or the antisense oligonucleotide in the cell.
In a preferred embodiment, HIV receptor cells introduced with a shRNA expression element containing a nucleic acid sequence encoding the RNA interference target obtained from the present invention can thus acquire an ability to inhibit HIV replication and viral gene expression.

Problems solved by technology

However, due to the high mutation rate of HIV and its complex pathogenesis, this type of approach could not completely eradicate the virus in vivo.
However, due to the different inhibition efficiency of different targets, not all RNA interference targets met the requirement of conventional design are able to inhibit the expression of target genes effectively.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • RNA interference target for treating aids
  • RNA interference target for treating aids
  • RNA interference target for treating aids

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design and Construction of the siRNA Expression Plasmid

Design of the RNA interference target sequence targeting HIV was carried out by:selecting a highly conservative region for the design of the siRNA sequence by “DNA walking” with HIV reference sequence as a target sequence;conducting BLAST search in the GenBank with the preliminarily selected siRNA sequence; andselecting sequences that have three or more different bases from non-targeting sequences as candidate sequences.

Construction of the siRNA expression plasmid: the expression vector of the siRNA is pSUPER vector (oligoengine company Cat. No VEC-PBS-0001 / 0002). For more information about the construction procedure, please refer to Experimental Protocol for the pSUPER vector from the company (www.oligoengine.com). A brief construction procedure is shown in the FIG. 1. Primers carrying the RNA interference sequence were synthesized, complementary primers were annealed and then ligated into the pSUPER vector digested with BgIII ...

example 2

Screening by Co-Transfection Assay for a RNA Interference Target which Can Effectively Inhibiting HIV

pNL4-3 plasmid (from Pasteur Institute; may also use other HIV-1 infectious cloning plasmid), a HIV-1 infectious cloning plasmid, has an ability to express HIV viral proteins and viral particles after being transfected into suitable Mammalian cells (for example, 293FT cells). P24 is a capsid protein of the HIV virus, which can indicate the expression level of the virus protein and virus particle by detecting the content of the p24 protein in the supernatant of the cell culture, and is positively correlated with the virus titer. Therefore, the efficiency of different siRNAs in inhibiting the replication of HIV-1 can be determined by co-transfecting the siRNA expression plasmids with HIV infectious cloning plasmid (pNL4-3 plasmid) in the 293FT cells, and detecting the expression level of p24 protein in the cells after co-transfection.

293FT cells (Invitrogen, Catalog #R700-07) were cult...

example 3

Construction of the Expression Vector and the Lentivirus Packaging Vector Expressing siRNA

Expression Vector:

The expression vector of the lentivirus system pDEST-MR (patent application number: 200510112917.1; Publication Number: CN1948475) used in this example comprises the MGMT (P140K) gene controlled by the mPGK promoter and an expression cassette for expressing siRNA controlled by the H1 promoter.

Method for Constructing the Expression Vectors pDEST-VIF037, pDEST-POL1102, pDEST-POL1217, pDEST-POL1327, pDEST-POL2252:

Gene fragments VIF037, POL1102, POL1217, POL1327, POL2252 (including as examples the RNA interference target sequences siVIF037 (SEQ ID NO: 24), siPOL1102 (SEQ ID NO: 8), siPOL1217 (SEQ ID NO: 10), siPOL1327 (SEQ ID NO: 29), siPOL2252 (SEQ ID NO: 22) shown in example 2, but may also include other RNA interference target sequences provided by the present invention) were synthesized respectively, and Age I site was added at the 5′ end of the fragments, Sma I site was added...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
molecular structureaaaaaaaaaa
nucleic acid sequence analysisaaaaaaaaaa
Login to view more

Abstract

The present invention relates to RNA interference target sequence targeting HIV for the treatment of AIDS. Based on the target sequence, recombinant expression vectors, packaging vectors and cells were constructed, which express a siRNA and / or a miRNA and / or a ribozyme and / or an antisense oligonucleotide targeting HIV. Also provided is the use of the recombinant expression vectors, packaging vectors and recombinant cells in the manufacture of a medicament for the treatment of AIDS.

Description

FIELD OF THE INVENTIONThe present invention relates to molecular biology, cell biology and gene therapy. More specifically, it relates to 32 RNA interference (RNAi) targets which can be used for AIDS treatment, recombinant expression vectors using the targets, and drugs and methods for treating AIDS obtained in a variety of ways using these targets.BACKGROUND OF THE INVENTIONAcquired Immune Deficiency Syndrome (AIDS) caused by HIV infection is one of most significant health threat faced by the world. Currently, AIDS has almost spread to countries around the world, and resulted in more than 40 million patients suffering from it, and nearly 30 million people were killed by it (WHO, Report on the Global AIDS Epidemic, 2004). In recent years, the spread of AIDS in China is growing rapidly, and the infected people have already amounted to 0.84 million. At present, the treatment of HIV infection is primarily through high-intensity anti-retrovirus therapy, such as through a combined use of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07H21/04C12N15/63C07H21/02C12N15/85C12N5/10C12N1/00A61K31/713A61K31/7088A61K35/12A61P31/18C12N15/113
CPCC12N15/1132C12N2310/14C12N2310/12C12N2310/11A61P31/18
Inventor CHENG, TONGZHANG, TAOZHANG, YALIMIAO, JIZHANG, JUNXIA, NINGSHAO
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products